IGF-1 LR3 is a synthetic peptide analog of natural insulin-like growth factor-1 (IGF-1) designed to enhance muscle growth, accelerate recovery, and support overall tissue repair and metabolic health.
 It achieves these effects by binding to IGF-1 receptors on cell surfaces, activating signaling pathways such as PI3K/Akt/mTOR that stimulate protein synthesis, inhibit protein breakdown, and promote cell proliferation and differentiation.
 The peptide's extended half-life—up to 30 hours—results from structural modifications, including an arginine substitution at position 3 and the addition of 13 amino acids at the N-terminus, which increase its bioavailability and potency compared to native IGF-1.
Promotes muscle hypertrophy and repair by stimulating satellite cell activation and increasing nitrogen retention in muscle tissue.
Enhances fat metabolism by promoting lipolysis and reducing fat storage, contributing to improved body composition and lean mass.
Supports recovery from intense exercise and injury by reducing muscle damage and inflammation, allowing for faster return to activity.
Improves bone density and joint health by stimulating osteoblast activity and collagen synthesis in tendons and ligaments.
Offers potential anti-aging benefits by supporting tissue regeneration, cognitive function, and metabolic flexibility.
May enhance glucose uptake and energy utilization, improving metabolic health and reducing fatigue during recovery.
Has been studied for applications in age-related muscle loss (sarcopenia), osteoporosis, and metabolic disorders.
As of January 7, 2026, ongoing research continues to explore its role in regenerative medicine, including neuroprotection and cardiac repair.
 However, potential risks such as hypoglycemia, joint pain, and concerns about tumor growth acceleration in individuals with pre-existing malignancies should be carefully considered.